For example, PARP inhibitors that target BRCA1/2 defects underlying HRR-deficiencies are also effective at killing cancer cells harboring defects in additional HRR genes, like RAD51, ATM, ATR, CHEK1, and RAD54B [106,131,132,133,134,135,136,137]. Here, RAD54B is linked to cancer.